Techno Blender
Digitally Yours.

Pfizer, BioNTech Ask FDA to Green Light Tweaked Covid-19 Vaccine

0 80



Pfizer Inc.

and

BioNTech SE

have asked U.S. health regulators to clear use of a Covid-19 shot modified to target the newest versions of the Omicron variant.

The U.S. Food and Drug Administration is expected to clear the shots for use in the coming weeks, in time for a planned fall booster campaign.

The Pfizer-BioNTech booster shot targets the original coronavirus plus the BA.4 and BA.5 subvariants of Omicron, which have become predominant in the U.S.

Pfizer and BioNTech said they have begun producing doses of the vaccines, and could begin supplying them to the U.S. government upon FDA clearance for a vaccination campaign that could start as soon as September.

“Having rapidly scaled up production, we are positioned to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters, if authorized, to help protect individuals and families as we prepare for potential fall and winter surges,” Pfizer Chief Executive

Albert Bourla

said in a press release.

The vaccines haven’t been tested in people in a clinical trial yet, though one is scheduled to begin this month, the companies said.

Studies in animals found a booster dose of the modified vaccine generated a strong immune response against the original strain and Omicron’s BA.1, BA.2 and BA.4/BA.5 variants, according to the companies.

Moderna Inc.

is also developing a bivalent vaccine and is expected to seek U.S. authorization soon.

Currently authorized Covid-19 vaccines, including those from Moderna and Pfizer-BioNTech, were designed to target the ancestral coronavirus strain that emerged in China in late 2019.

However, some research has found these shots offer less protection against the Omicron variant and its subvariants.

Earlier, Pfizer and BioNTech had pursued a modified vaccine targeting the original Omicron variant. That vaccine produced a significantly stronger immune response in study subjects than the companies’ currently available vaccine.

Since the start of the Covid-19 pandemic in 2020, the scientific understanding of its transmission and prevention has evolved. WSJ’s Daniela Hernandez explains what strategies have worked for stemming the spread of the virus and which are outdated in 2022. Illustration: Adele Morgan

The FDA, however, then asked the companies to manufacture a vaccine targeting the Omicron subvariants.

Some other countries have preferred booster shots targeting the original Omicron variant. U.K. health regulators on Aug. 15 authorized the use of Moderna’s BA.1-targeted bivalent booster shot.

Pfizer and the U.S. agreed to a $3.2 billion deal for 105 million vaccine doses to the U.S. this fall, including the modified shots.

Write to Jared S. Hopkins at [email protected]

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8



Pfizer Inc.

and

BioNTech SE

have asked U.S. health regulators to clear use of a Covid-19 shot modified to target the newest versions of the Omicron variant.

The U.S. Food and Drug Administration is expected to clear the shots for use in the coming weeks, in time for a planned fall booster campaign.

The Pfizer-BioNTech booster shot targets the original coronavirus plus the BA.4 and BA.5 subvariants of Omicron, which have become predominant in the U.S.

Pfizer and BioNTech said they have begun producing doses of the vaccines, and could begin supplying them to the U.S. government upon FDA clearance for a vaccination campaign that could start as soon as September.

“Having rapidly scaled up production, we are positioned to immediately begin distribution of the bivalent Omicron BA.4/BA.5 boosters, if authorized, to help protect individuals and families as we prepare for potential fall and winter surges,” Pfizer Chief Executive

Albert Bourla

said in a press release.

The vaccines haven’t been tested in people in a clinical trial yet, though one is scheduled to begin this month, the companies said.

Studies in animals found a booster dose of the modified vaccine generated a strong immune response against the original strain and Omicron’s BA.1, BA.2 and BA.4/BA.5 variants, according to the companies.

Moderna Inc.

is also developing a bivalent vaccine and is expected to seek U.S. authorization soon.

Currently authorized Covid-19 vaccines, including those from Moderna and Pfizer-BioNTech, were designed to target the ancestral coronavirus strain that emerged in China in late 2019.

However, some research has found these shots offer less protection against the Omicron variant and its subvariants.

Earlier, Pfizer and BioNTech had pursued a modified vaccine targeting the original Omicron variant. That vaccine produced a significantly stronger immune response in study subjects than the companies’ currently available vaccine.

Since the start of the Covid-19 pandemic in 2020, the scientific understanding of its transmission and prevention has evolved. WSJ’s Daniela Hernandez explains what strategies have worked for stemming the spread of the virus and which are outdated in 2022. Illustration: Adele Morgan

The FDA, however, then asked the companies to manufacture a vaccine targeting the Omicron subvariants.

Some other countries have preferred booster shots targeting the original Omicron variant. U.K. health regulators on Aug. 15 authorized the use of Moderna’s BA.1-targeted bivalent booster shot.

Pfizer and the U.S. agreed to a $3.2 billion deal for 105 million vaccine doses to the U.S. this fall, including the modified shots.

Write to Jared S. Hopkins at [email protected]

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment